PapYour posts worry me, the company has an obligation to keep the market informed. Providing information about contracts and timing to someone that calls out of the blue seems a little odd.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%